Bayer and BMS Win NICE Round On Stivarga And Opdivo
Executive Summary
Bayer and Bristol-Myers Squibb have convinced the UK’s NICE to revisit its earlier recommendations and make their cancer treatments, Stivarga and Opdivo respectively, available for patients on the National Health Service.